Ramiven 100 mg Tablet

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Ramiven 100 mg tablet (abemaciclib) pack

Product Overview

Ramiven 100 mg Tablet contains abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Its labelling describes it as a treatment for hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, used with endocrine therapy or, in certain settings, on its own, and described as slowing the growth of cancer cells.

Active ingredient
Abemaciclib
Dosage form
Oral tablet
Therapeutic class
CDK 4/6 inhibitor (antineoplastic)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with abemaciclib and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Described for HR-positive, HER2-negative advanced or metastatic breast cancer
  • Described as used together with endocrine therapy, or alone after prior hormonal therapy
  • Described as slowing division and growth of cancer cells
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Taken by mouth, with or without food, at the dose and schedule prescribed
  • Often described as taken together with another (endocrine) medicine as directed by the doctor
  • Duration depends on individual response; the dose should not be changed without the prescriber
  • Regular blood tests are described during treatment

Described Side Effects

Commonly described side effects include:

  • Diarrhoea
  • Fatigue
  • Nausea and vomiting
  • Loss of appetite
  • Headache
  • Cough
  • Joint pain
  • Hair thinning
  • Described as possibly lowering white blood cell counts (neutropenia), increasing infection risk, and as possibly causing blood clots

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Signs of infection (fever, chills), or of a blood clot (leg swelling, chest pain, breathlessness), should be reported promptly
  • Persistent or severe diarrhoea should be managed as directed and reported
  • Existing medical conditions and all other medicines should be disclosed to the doctor
  • Pregnancy, planned pregnancy or breastfeeding should be discussed with the prescriber

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling it contains abemaciclib, a CDK4/6 inhibitor, and is described for HR-positive, HER2-negative advanced or metastatic breast cancer. SDO Pharma has not independently verified these claims.

Its labelling describes it as commonly used together with endocrine therapy; the treating doctor sets the combination and dose.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services